Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma

References

• Grignon DJ, Che M. Clear cell renal cell carcinoma. Clin Lab Med. 2005;25(2):305–316. doi:10.1016/j.cll.2005.01.012
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524. doi:10.3322/caac.21411
   PubMed Web of Science ®Google Scholar
• Tamura T, Yanai H, Savitsky D, et al. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535–584. doi:10.1146/annurev.immunol.26.021607.090400
   PubMed Web of Science ®Google Scholar
• Yan Y, Zheng L, Du Q, et al. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol, Immunother. 2020;69(9):1891–1903. doi:10.1007/s00262-020-02586-9
   PubMed Web of Science ®Google Scholar
• Rho SB, Lee SH, Byun HJ, et al. IRF-1 inhibits angiogenic activity of HPV16 E6 oncoprotein in cervical cancer. Int J Mol Sci. 2020;21(20):7622.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Liang L, Li J, et al. IRF-2 inhibits gastric cancer invasion and migration by down-regulating MMP-1. Dig Dis Sci. 2020;65(1):168–177. doi:10.1007/s10620-019-05739-8
   PubMed Web of Science ®Google Scholar
• Gambara G, Desideri M, Stoppacciaro A, et al. TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med. 2015;19(2):327–339. doi:10.1111/jcmm.12379
   PubMed Web of Science ®Google Scholar
• Biswas SK, Gangi L, Paul S, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107(5):2112–2122. doi:10.1182/blood-2005-01-0428
   PubMed Web of Science ®Google Scholar
• Huber M, Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. Eur J Immunol. 2014;44(7):1886–1895. doi:10.1002/eji.201344279
   PubMed Web of Science ®Google Scholar
• Acquaviva J, Chen X, Ren R. IRF-4 functions as a tumor suppressor in early B-cell development. Blood. 2008;112(9):3798–3806. doi:10.1182/blood-2007-10-117838
   PubMed Web of Science ®Google Scholar
• Ortmann CA, Burchert A, Lzle HK, et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res. 2005;33(21):6895–6905. doi:10.1093/nar/gki1001
   PubMed Web of Science ®Google Scholar
• Massimino M, Vigneri P, Fallica M, et al. IRF5 promotes the proliferation of human thyroid cancer cells. Mol Cancer. 2012;11(21):1–8. doi:10.1186/1476-4598-11-21.
   PubMed Web of Science ®Google Scholar
• Guo J, Wang X, Wang Y, et al. A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer. Lung Cancer. 2019;135:47–55. doi:10.1016/j.lungcan.2019.07.008
   PubMed Web of Science ®Google Scholar
• Xu HF, Huang TJ, Yang Q, et al. Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression. Cancer Manag Res. 2019;11:5557–5572. doi:10.2147/CMAR.S203060
   PubMed Web of Science ®Google Scholar
• Li D, Cheng P, Wang J, et al. IRF6 is directly regulated by ZEB1 and ELF3, and predicts a favorable prognosis in gastric cancer. Front Oncol. 2019;9:220. doi:10.3389/fonc.2019.00220
   PubMed Web of Science ®Google Scholar
• Ren Y, Dong J, He P. miR-587 promotes cervical cancer by repressing interferon regulatory factor 6. J Gene Med. 2020;22(11):e3257.
   PubMed Web of Science ®Google Scholar
• Nobeyama Y, Nakagawa H. Silencing of interferon regulatory factor gene 6 in melanoma. PLoS One. 2017;12(9):e0184444. doi:10.1371/journal.pone.0184444
   PubMed Web of Science ®Google Scholar
• Bidwell BN, Slaney CY, Withana NP, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18(8):1224–1231. doi:10.1038/nm.2830
   PubMed Web of Science ®Google Scholar
• Li Y, Huang R, Wang L, et al. microRNA-762 promotes breast cancer cell proliferation and invasion by targeting IRF7 expression. Cell Prolif. 2015;48(6):643–649. doi:10.1111/cpr.12223
   PubMed Web of Science ®Google Scholar
• Meyer MA, Baer JM, Knolhoff BL, et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun. 2018;9(1):1250. doi:10.1038/s41467-018-03600-6
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang L, Li L, et al. Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis. Cancer Lett. 2014;354(2):227–234. doi:10.1016/j.canlet.2014.07.040
   PubMed Web of Science ®Google Scholar
• Tian WL, Guo R, Wang F, et al. The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia. Exp Cell Res. 2018;365(2):185–193. doi:10.1016/j.yexcr.2018.02.036
   PubMed Web of Science ®Google Scholar
• Brunn D, Turkowski K. Interferon regulatory factor 9 promotes lung cancer progression via regulation of versican. Cancers. 2021;13(2):208.
   PubMed Web of Science ®Google Scholar
• Hutter C, Zenklusen JC. The cancer genome atlas: creating lasting value beyond its data. Cell. 2018;173(2):283–285. doi:10.1016/j.cell.2018.03.042
   PubMed Web of Science ®Google Scholar
• Zhang J, Bajari R, Andric D. The international cancer genome consortium data portal. Nature. 2019;37(4):367–369.
   Web of Science ®Google Scholar
• Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11(16):5730–5739. doi:10.1158/1078-0432.CCR-04-2225
   PubMed Web of Science ®Google Scholar
• A-llopis PE, Liao A, BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751–759. doi:10.1038/ng.2323
   PubMed Web of Science ®Google Scholar
• A-llopis PE, Brugarolas J. Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications. Nat Protoc. 2013;8(11):2240–2255. doi:10.1038/nprot.2013.141
   PubMed Web of Science ®Google Scholar
• Von Roemeling CA, Radisky DC, Marlow LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74(17):4796–4810. doi:10.1158/0008-5472.CAN-14-0210
   PubMed Web of Science ®Google Scholar
• Wotschofsky Z, Gummlich L, Liep J, et al. Integrated microRNA and mRNA signature associated with the transition from the locally confined to the metastasized clear cell renal cell carcinoma exemplified by miR-146-5p. PLoS One. 2016;11(2):e0148746. doi:10.1371/journal.pone.0148746
   PubMed Web of Science ®Google Scholar
• Liep J, Kilic E, Meyer HA, et al. Cooperative effect of miR-141-3p and miR-145-5p in the regulation of targets in clear cell renal cell carcinoma. PLoS One. 2016;11(6):e0157801. doi:10.1371/journal.pone.0157801
   PubMed Web of Science ®Google Scholar
• Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021;11(1):6047. doi:10.1038/s41598-021-84787-5
   Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, NY). 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Colwill K, GR SLUND S. A roadmap to generate renewable protein binders to the human proteome. Nat Methods. 2011;8(7):551–558. doi:10.1038/nmeth.1607
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature. 2019;10(1):1523.
   Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR. Robust enumeration of cell subsets from tissue expression profiles. Nature. 2015;12(5):453–457.
   Web of Science ®Google Scholar
• O’neill LA, Bowie AG. Sensing and signaling in antiviral innate immunity. Current Biol. 2010;20(7):R328–R333. doi:10.1016/j.cub.2010.01.044
   PubMed Web of Science ®Google Scholar
• Sharma S, Tenoever BR, Grandvaux N, et al. Triggering the interferon antiviral response through an IKK-related pathway. Science. 2003;300(5622):1148–1151. doi:10.1126/science.1081315
   PubMed Web of Science ®Google Scholar
• Shinobu N, Iwamura T, Yoneyama M, et al. Involvement of TIRAP/MAL in signaling for the activation of interferon regulatory factor 3 by lipopolysaccharide. FEBS Lett. 2002;517(1–3):251–256. doi:10.1016/S0014-5793(02)02636-4
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang H, Wu X, et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. Nature. 2018;563(7729):131–136. doi:10.1038/s41586-018-0629-6
   PubMed Web of Science ®Google Scholar
• Kim JW, Cochran JR. Targeting ligand-receptor interactions for development of cancer therapeutics. Curr Opin Chem Biol. 2017;38:62–69. doi:10.1016/j.cbpa.2017.03.010
   PubMed Web of Science ®Google Scholar
• Spangler JB, Moraga I, Mendoza JL, et al. Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33:139–167. doi:10.1146/annurev-immunol-032713-120211
   PubMed Web of Science ®Google Scholar
• Cui C, Merritt R, Fu L, et al. Targeting calcium signaling in cancer therapy. Acta Pharmaceutica Sinica B. 2017;7(1):3–17. doi:10.1016/j.apsb.2016.11.001
   PubMed Web of Science ®Google Scholar
• Saleh R, Elkord E. FoxP3(+) T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174–185. doi:10.1016/j.canlet.2020.07.022
   PubMed Web of Science ®Google Scholar
• Cuende J, Li Nart S, Dedobbeleer O, et al. Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci Transl Med. 2015;7(284):284ra56. doi:10.1126/scitranslmed.aaa1983
   PubMed Web of Science ®Google Scholar
• Abril-rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors. Cancer Cell. 2017;31(6):848–e1. doi:10.1016/j.ccell.2017.05.010
   PubMed Web of Science ®Google Scholar